About - Practical Recommendations in Immuno and Molecular Oncology (PRIMO)

The 2024 Annual
PRIMO Meeting

The PRIMO meeting Co-Chairs, Steering Committee, and Education Committee have curated an agenda to meet the educational needs of all attendees and will focus on the following key areas:
  • Practical considerations of applying biomarkers and targeted therapy
  • Integration of immunotherapy, with a focus on novel management approaches
  • Patient selection, as well as timing and sequencing of therapy
  • Dealing with important trends, such as big data and defining value in cancer care
Wednesday, February 7, 2024
12:00 PM – 8:00 PM
6:30 PM – 8:00 PM
Welcome reception at the Lu'au Grounds at the Royal Sonesta Kaua'i Resort
Join us in honoring the 2024 Women in Oncology Award winner: Dr. Barbara Goff
Thursday, February 8, 2024
6:30 AM – 3:00 PM
Exhibits & VIP Lounge Open
7:00 AM – 7:05 AM
Meeting Welcome
7:05 AM – 7:10 AM
Program Overview
Hematologic Malignancies – Session Chair – Julie M. Vose, MD, MBA
7:10 AM – 7:30 AM
Update on novel therapies for NHL
7:30 AM – 7:50 AM
Role of Immunotherapy in Myeloma
7:50 AM – 8:10 AM
AML: Where Are We Now and Where Are We Going?
8:10 AM – 8:30 AM
Update on Novel Therapies for NHL
Product Theater
9:00 AM – 9:45 AM
Product Theater Breakfast Showcase (Non-CE)
9:45 AM – 10:00 AM
Energize and Visit Exhibits
10:00 AM – 10:15 AM
WIO Keynote Presentation - The Chutes and Ladders of Academic Medicine: Learning How to Fail Up
Barbara Goff, MD
Multidisciplinary Approach to Cancer – Session Co-Chairs: –   Jorge J. García, PharmD, MS, MHA, MBA, FACHE
  Shane Morita, MD, MS, PhD, FACS
10:15 AM – 10:35 AM
Payor Benefits Design Changing Oncology Care Delivery
10:35 AM – 10:40 AM
10:40 AM – 11:00 AM
Gene Therapy in Oncology: Past, Present and Future
11:00 AM – 11:05 AM
Product Theater
11:45 AM – 12:30 PM
Product Theater Lunch Showcase (Non-CE)
12:30 PM – 12:45 PM
Desserts and Visit Exhibits | VIP Lounge Open
Gastrointestinal Malignancies – Session Chair – Rachna T. Shroff, MD, MS, FASCO
12:45 PM – 1:05 PM
Molecular and Immunotherapy Updates in Colon Cancer
1:05 PM – 1:25 PM
Immunotherapy in HCC
1:05 PM – 1:45 PM
Q&A Panel Discussion
Evening Reception*
5:30 PM – 7:00 PM
Sunset Mingle Networking Event (*by invite only)
Friday, February 9, 2024
6:30 AM – 3:00 PM
Exhibits & VIP Lounge Open
7:00 AM – 7:05 AM
Welcome and Day 2 Program Overview
Melanoma and Brain Tumors - Session Chair:   Sanjiv S. Agarwala, MD
7:05 AM – 7:20 AM
Melanoma: Have we Hit a Plateau or are we Making Progress?
7:20 AM – 7:25 AM
7:30 AM – 7:50 AM
New Appraches and Advances in the Therapy of Gliomas
7:40 AM – 7:45 AM
Product Theater
8:00 AM – 8:45 AM
Product Theater Breakfast Showcase (Non-CE)
8:45 AM – 9:15 AM
VIP Lounge Open
Lung & Aerodigestive Cancer – Session Chair – Luis E. Raez, MD, FACP, FCCP
9:15 AM – 9:30 AM
New Agents after Immunotherapy Resistance
9:30 AM – 9:45 AM
What’s New in EGFR, ALK, RET and c-MET
9:45 AM – 10:00 AM
Neoadjuvant and Adjuvant Immunotherapy
10:00 AM – 10:15 AM
Small Cell Lung Cancer
10:25 AM – 11:10 AM
Lung Cancer Tumor Board with CEN

Targeted Therapy Patient (Ros1)
Chemotherapy/Immunotherapy Patient Second Line and Beyond
Neoadjuvant vs Adjuvant Immunotherapy
Product Theater
11:15 AM – 12:00 PM
Product Theater Lunch Showcase (Non-CE)
12:00 PM – 12:15 PM
Desserts and Visit Exhibits | VIP Lounge Open
Genitourinary - Session Co-Chairs: Ravi Madan, MD and Ulka Vaishampayan, MD
12:15 PM – 12:35 PM
Updates in Systemic Therapy of Urothelial Cancer
Ulka Vaishampayan, MD
12:35 PM – 12:55 PM
Adjuvant Therapy for Renal Cell Carcinoma: Hope or Hype?
12:55 PM – 1:05 PM
PARP Inhibitors in Prostate Cancer: Who, When, and Why (not)
1:05 PM – 1:45 PM
Genitourinary Tumor Board with CEN

Case with Advanced Bladder Cancer
Case of Metastatic RCC First-Line Therapy
Case of PSMA PET Imaging – Too Much Information or Too Little?
ModeratorRavi A. Madan, MD

Ulka Vaishampayan, MD
Guru Sonpavde, MD
Ravi A. Madan, MD
Saturday, February 10, 2024
6:30 AM – 11:00 AM
Exhibits open
7:00 AM – 7:05 AM
Welcome and Day 3 Program Overview
Breast Cancer – Session Chair - Hope S. Rugo, MD, FASCO
7:05 AM – 7:25 AM
Sequencing Endocrine Therapy and Targeted Agents for the Treatment of Hormone Receptor Positive Metastatic Breast Cancer
Komal Jhaveri, MD, FACP
7:25 AM – 7:45 AM
Antibody Drug Conjugates: New Directions, New Agents!
7:45 AM – 8:05 AM
Advances in the Treatment of High Risk Early Stage Hormone Receptor Positive Breast Cancer
8:05 AM – 8:25 AM
Immunotherapy for Triple Negative Breast Cancer: Optimal Chemotherapy Partners, New Directors, and Managing Toxicity
8:25 AM – 8:35 AM
Q&A Panel Discussion
Breast Tumor Board – Moderator - Hope S. Rugo, MD, FASCO
8:35 AM – 9:25 AM
Join Forces with our Breast KOLs and Participate in an Active Discussion on the Most Interesting Breast Cases
Product Theater
9:30 AM – 10:15 AM
Product Theater Breakfast Showcase (Non-CE)
10:15 AM – 10:30 AM
Energize and Visit Exhibits
Other Women’s Cancers – Session Chair – Don S. Dizon, MD, FACP, FASCO
10:30 AM – 10:45 AM
Controversies in the Management of Ovarian Cancer: A Focus on First-Line Treatment
10:45 AM – 11:00 AM
Immunotherapy For Uterine Cancer: New Standards For Upfront Treatment For Advanced Or Recurrent Disease.
11:00 AM – 11:15 AM
Treating Advanced or Metastatic Cervical Cancer: ADCs, VEGF Inhibitors, and Immunotherapy
11:15 AM – 11:30 AM
Advancing Precision In Endometrial Carcinoma: Molecular Classification And Its Impact On Prognosis And Treatment. Are We Ready?
Barbara Goff, MD
11:30 AM – 11:50 AM
Q&A Panel Discussion
11:50 AM – 11:55 AM
Closing Remarks

We acknowledge commercial support from Taiho Oncology, Exelixis, Pfizer, AstraZeneca, and Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.


Registration Type Early
01/01/2022 - 07/31/2022
08/01/2022 - 12/31/2022
01/01/2024 - 02/10/2024
Allied Health

Join your colleagues and explore key developments in cancer care over the past 12 months as well as the anticipated advances that you and your patients will likely see in the upcoming year.

Primo Demographics

Target Audience

This activity has been designed to meet the educational needs of Academic and Community Practitioners, as well as Registered Nurses and Advanced Practice Registered Nurses, Pharmacists and Physician Associates from all oncology specialties, treating all disease sites involved in the care of patients with cancer.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Describe the rationale for mechanisms of action for molecular targeted and immunologic therapies used to treat cancer today;
  • Summarize recent advances in targeted and immunologic treatment of hematologic malignancies and solid tumors;
  • Identify patients who are appropriate candidates for targeted and immunologic therapies;
  • Implement strategies from a healthcare team approach to reduce treatment-related toxicities, and optimize patient outcomes;
  • Discuss promising targeted and immunologic approaches being tested in late-stage clinical trials.

PRIMO 2020
at a Glance

26 Conference Sponsors

The Practical Recommendations in Immuno and Molecular Oncology Meeting is a unique opportunity to receive CE credits while staying ahead of the latest advances in immuno and molecular oncology.

The Annual PRIMO Meeting is designed to summarize key developments in cancer care over the past 12 months and features anticipated advances that you and your patients will likely see in the upcoming year.

Accredited by:

MEC Logo

Accreditation and Credit Statements

JA Commendation Mark
In support of improving patient care, The Medical Educator Consortium is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
IPCE Credit Logo

This activity was planned by and for the healthcare team, and learners will receive 12.25 Interprofessional Continuing Education (IPCE) credit for learning and change.


The Medical Educator Consortium designates this live activity for a maximum of 12.25 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


“Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 12.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.”

Learner participation will be shared through the ACCME’s Program and Activity Reporting System (PARS)


The Medical Educator Consortium designates this activity for 12.25 contact hours.


This Application-based activity has been approved for 12.25 contact hours (1.2 CEU) by The Medical Educator Consortium. The Universal Activity Number for this program is JA4008179-0000-23-002-L01-P. Your CE credits will be electronically submitted to CPE Monitor® within 60 days upon successful completion of the activity.

Physician Associate

AAPA Cat1 CME logo

The Medical Educator Consortium has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 12.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.


The Medical Educator Consortium (MEC) adheres to the Joint Accreditation Criteria and the ACCME Standards for Integrity and Independence in Accredited Continuing Education.  As a Joint Accreditation (JA) provider, decisions in the planning process of this conference were made free of the control of ineligible companies. All persons that will be in a position to control the content of the CE Activity are required to disclose all relevant financial relationships, regardless of the amount, that they have had in the past 24 months with ineligible companies. MEC has implemented a mechanism to identify, mitigate and disclose relevant financial relationships prior to the education activity being delivered to learners. A Disclosure Index document outlining this information will be made available to participants prior to the educational activity. The source of all commercial support from ineligible companies will also be disclosed to learners prior to the beginning of the educational activity. CE activities must be balanced, independent of commercial bias, and designed to improve quality in health care. All recommendations involving clinical medicine must be based on evidence within the medical profession. 


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contradictions, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contradictions and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.